Published in Liver Transpl Surg on May 01, 1997
Treatment of alcoholic liver disease. Therap Adv Gastroenterol (2011) 1.06
Liver transplantation for alcoholic liver disease. World J Gastroenterol (2010) 0.91
Indications and contraindications for liver transplantation. Int J Hepatol (2011) 0.88
Indications for referral and assessment in adult liver transplantation: a clinical guideline. British Society of Gastroenterology. Gut (1999) 0.85
Liver transplantation in acute alcoholic hepatitis: Current status and future development. World J Hepatol (2011) 0.84
Alcoholic Hepatitis. Curr Treat Options Gastroenterol (2001) 0.78
Liver transplantation for chronic liver disease: advances and controversies in an era of organ shortages. Postgrad Med J (2002) 0.78
Management of alcoholic hepatitis: Current concepts. World J Hepatol (2012) 0.75
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89
Examination and characterization of distribution system biofilms. Appl Environ Microbiol (1987) 5.85
Occurrence of Giardia and Cryptosporidium spp. in surface water supplies. Appl Environ Microbiol (1991) 5.31
Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01
Intestinal transplantation in composite visceral grafts or alone. Ann Surg (1992) 4.96
Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32
Inactivation of biofilm bacteria. Appl Environ Microbiol (1988) 4.29
Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18
A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology (1990) 4.02
Liver transplantation in the United States, 1999-2008. Am J Transplant (2010) 3.92
Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63
Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40
Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Intern Med (1996) 3.38
Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34
Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29
Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26
Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18
The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14
Motor responses to sudden limb displacements in primates with specific CNS lesions and in human patients with motor system disorders. Can J Neurol Sci (1975) 3.13
Common inheritance of susceptibility to colonic adenomatous polyps and associated colorectal cancers. N Engl J Med (1988) 3.01
Giardia and Cryptosporidium spp. in filtered drinking water supplies. Appl Environ Microbiol (1991) 2.95
Outcome analysis of 71 clinical intestinal transplantations. Ann Surg (1995) 2.95
Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91
Functional characterization of infiltrating T lymphocytes in human hepatic allografts. Hum Immunol (1986) 2.84
Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc (1993) 2.81
Factors promoting survival of bacteria in chlorinated water supplies. Appl Environ Microbiol (1988) 2.80
Cadaveric small bowel and small bowel-liver transplantation in humans. Transplantation (1992) 2.75
A case series of transplant recipients who despite immunosuppression developed inflammatory bowel disease. Am J Gastroenterol (1997) 2.65
Bacterial nutrients in drinking water. Appl Environ Microbiol (1991) 2.62
Management of intestinal transplantation in humans. Transplant Proc (1992) 2.62
Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60
Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation (1990) 2.59
Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59
The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology (1997) 2.57
FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation (1994) 2.50
Pregnancy after liver transplantation under tacrolimus. Transplantation (1997) 2.50
Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc (1990) 2.48
Prioritization and organ distribution for liver transplantation. JAMA (1994) 2.38
The antibody crossmatch in liver transplantation. Surgery (1986) 2.33
The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg (1994) 2.32
Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg (1998) 2.31
Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression. Transplant Proc (1991) 2.28
Assessment of five-year experience with abdominal organ cluster transplantation. J Am Coll Surg (1995) 2.25
Should HLA mismatch acceptability for sensitized transplant candidates be determined at the high-resolution rather than the antigen level? Am J Transplant (2015) 2.24
Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant (2006) 2.22
Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg (1999) 2.22
Three years clinical experience with intestinal transplantation. J Am Coll Surg (1994) 2.20
Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation (1992) 2.20
The nature of unexplained chronic aminotransferase elevations of a mild to moderate degree in asymptomatic patients. Hepatology (1989) 2.19
Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology (1999) 2.19
Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg (1997) 2.16
Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis (1996) 2.12
One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. Transplant Proc (1991) 2.10
A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation (1995) 2.09
The side effects of FK 506 in humans. Transplant Proc (1990) 2.08
Randomised trialomania? The multicentre liver transplant trials of tacrolimus. Lancet (1995) 2.04
Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg (1998) 1.99
Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol. N Engl J Med (1987) 1.98
Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. Transplantation (1991) 1.95
FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. Lancet (1990) 1.94
Successful hamster-to-rat liver xenotransplantation under FK506 immunosuppression induces unresponsiveness to hamster heart and skin. Transplantation (1993) 1.94
Acute liver failure: clinical features, outcome analysis, and applicability of prognostic criteria. Liver Transpl (2000) 1.88
Growth of donor-derived dendritic cells from the bone marrow of murine liver allograft recipients in response to granulocyte/macrophage colony-stimulating factor. J Exp Med (1995) 1.88
Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients. Transplantation (1996) 1.86
Experience with liver and kidney allografts from non-heart-beating donors. Transplantation (1995) 1.83
Orthotopic liver transplantation in the mouse. Transplantation (1991) 1.82
Apoptosis within spontaneously accepted mouse liver allografts: evidence for deletion of cytotoxic T cells and implications for tolerance induction. J Immunol (1997) 1.81
Pathologic observations in human allograft recipients treated with FK 506. Transplant Proc (1990) 1.80
Early events in liver allograft rejection. Delineation of sites of simultaneous intragraft and recipient lymphoid tissue sensitization. Am J Pathol (1991) 1.78
Monitoring and treatment of intestinal allograft rejection in humans. Transplant Proc (1993) 1.78
Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy. Transplant Proc (1991) 1.77
Use of FK 506 in pediatric patients. Transplant Proc (1991) 1.77
Liver resection for hilar and peripheral cholangiocarcinomas: a study of 62 cases. Ann Surg (1998) 1.72
Randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone after renal transplantation: preliminary report. Transplant Proc (1993) 1.72
Parkinson's disease and exposure to agricultural work and pesticide chemicals. Neurology (1992) 1.71
Transplantation. JAMA (1990) 1.71
Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation (1999) 1.70
The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient. Liver Transpl Surg (1997) 1.68
Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: evidence of active replication in monocytes/macrophages and lymphocytes. J Infect Dis (2000) 1.66
Interactions between bronchoalveolar lymphocytes and macrophages in heart-lung transplant recipients. Hum Immunol (1985) 1.65
Resetting of tremor by mechanical perturbations: a comparison of essential tremor and parkinsonian tremor. Ann Neurol (1981) 1.64
Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology (1996) 1.62
Histocompatibility and liver transplant outcome. Does HLA exert a dualistic effect? Transplantation (1988) 1.61
Synchronization of human motor units: possible roles of exercise and supraspinal reflexes. Electroencephalogr Clin Neurophysiol (1975) 1.60
Clinical and radiologic features of cerebral edema in fulminant hepatic failure. Mayo Clin Proc (1995) 1.59
Incidence and risk factors associated with the development of cytomegalovirus disease after intestinal transplantation. Transplantation (1995) 1.59
Weaning of immunosuppression in long-term liver transplant recipients. Transplantation (1995) 1.59
Fibrosing cytolytic liver failure secondary to recurrent hepatitis B after liver transplantation. Gastroenterology (1992) 1.58
The spectrum of portal vein thrombosis in liver transplantation. Ann Surg (1991) 1.58
Dominant inheritance of adenomatous colonic polyps and colorectal cancer. N Engl J Med (1985) 1.58